Thinly traded nano cap Caladrius Biosciences (CLBS -22.9%) is down more than double volume, albeit on turnover of only 62K shares, on the heels of preliminary results from a Phase 2a clinical trial evaluating CLB03 in adolescents with recent-onset type 1 diabetes (T1D).
After a year's follow-up there was no improvement in the primary endpoint of preservation of C-peptide levels compared to placebo.
Two-year follow-up data are next up.
CLBS03 is a autologous cell therapy consisting of the patient's own T cells that have been expanded and re-engineered via a proprietary method.
Subscribe for full text news in your inbox